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CHAPTER 1 INTRODUCTION
1.1. Background
Cancer is known as a group of diseases characterized by cellular mutation
and uncontrolled growth.

If the spread of the cancer cells is out of control,

eventually It can cause death. It is estimated that approximately 1,700,000 of new
cancer cases occurred and over 600,000 patients are expected to die of cancer in
the US, which translates to more than 1,600 people per day in 2017 [1]. Most of
the current treatments for cancer are surgery [2,3] which is often combined with
chemotherapy [4–6], hormonal therapy [7], radiation [8] and targeted therapy [9].
Currently, chemotherapy is the first line therapy for patients after having some
type of surgery for cancer [10,11]. However, the major limitations of neoadjuvant
chemotherapy is the non-specific distribution in the human body which often cause
unexpected side effects to normal cells [12]. Multiple drug resistance (MDR) of
cancer cells is another limitation of chemotherapeutic drugs[13,14]. The severe
non-target and multiple drug resistance could be overcome if drugs could be
delivered to targeted site towards cancer cells. Targeted therapeutics have a great
clinical potential in increasing the cytotoxicity of cancer cells and decreasing side
effects to normal cells [15].

1.2. Cerium oxide nanoparticles and its anti-cancer effects by reactive
oxygen species modulation
Nanotechnology using organic and inorganic materials can play a meaningful role
in addressing the selective therapy of cancers. The application of nanotechnology
has seen rapid growth in many areas such as, [16], nanomedicine products[17],
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imaging[18] and drug delivery[19]. Different metal oxide nanoparticles, including
iron oxide nanoparticles[20–22], zinc oxide nanoparticles[23], gallium oxide
nanoparticles[24], have been widely investigated for their anti-cancer effects.
Cerium oxide nanoparticles have the ability to undergo oxidation-reduction cycles
between valence state of Ce+3 and Ce+4 which is related to redox reactions[25,26].
Cerium oxide displays a unique pH-dependent antioxidant activity. At normal pH,
it shows antioxidant properties which can protect the cells by scavenging reactive
oxygen species [27], whereas in acidic pH (cancer cells environment) it presents
more cytotoxicity by mediating oxidative stress to the cancer cells[28]. Along these
lines, redox responsive cerium oxide nanoparticles can play a versatile role in
cancer therapy due to reactive oxygen species. The physicochemical
characterization, cytotoxicity of cerium oxide nanoparticles and the quantification
of intracellular levels of reactive oxygen species were evaluated in detail.

1.3. Targeted anticancer drug delivery using hyaluronic acid
engineered nanomicelles
1.3.1 CDF (3,4-difluorobenzylidene diferuloylmethane) – highly potent but
extremely lipophilic anticancer drug
In our previous study, 3,4-difluorobenzylidene diferuloylmethane or in short
CDF was synthesized that showed better bioavailability than its natural analog,
diferuloylmethane, in various type of cell lines, include pancreatic, breast, lung,
cervical and ovarian cancers. It has several folds higher stability with better halflife compare with its natural analog, curcumin[29]. CDF can cause inactivation of
carcinomas signaling pathways consistent with miR-21 down-regulation of
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transcription of DNA, NF-kb, and up-regulation of MiR-200 and phosphatase and
tensin homolog (PTEN)[30–32]. However, the major issue limiting CDF for
preclinical and clinical translation is its highly hydrophobicity. Therefore, In our
earlier studies, we successful synthesized different formulation including
dendrimer, nanoparticles and liposomes to overcome CDF’s solubility issue that
resulted in significant increase in chemotherapeutic efficacy[12,18,33–37].
1.3.2 Hyaluronic Acid Engineered Vitamin E TPGS nanomicelles in targeted
drug delivery
1.3.2.1 What are nanomicelles?
Nanomicelles are constructed using amphiphilic polymers which can selfassemble into particles with the core-shell architecture having nano-sized
dimension. The inner core is composed of the hydrophobic domain which can
encapsulate the hydrophobic chemotherapeutic agents, and the outer shell mostly
consists of the hydrophilic group which can improve the solubility of the
nanocarriers

and

protect

the

chemotherapeutic

drugs

from

premature

degradation[38–41]. The nano-range of the micelles helps the formulation
effectively to target tumor through the enhanced permeability and retention (EPR) effect[42,43]. The hydrophilic part of amphiphilic polymers can be modified with
different targeting ligand such as folic acid[44,45], hyaluronic acid[34], and
transferrin[46–48] to achieve active targeting. In recent years, nanomicelles have
received growing scientific attention due to their effectiveness in safety and
efficacy for cancer therapy. Currently, several polymeric nanomicelles-based
formulations

have

been

moved

into

clinical

trials

including

Genexol-
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PM[49,50]NK105[51,52], SP1049[53,54], Docetaxel-loaded targeted polymeric
nanoparticles (DTXL-TNP)[55].
1.3.2.2 Tumor passive targeting strategy of nanomicelles
Targeted nano-sized chemotherapeutic strategies are generally classified
into passive targeting and active targeting. Tumor tissue has a unique property to
increase the accumulation of small size nanoparticles (<200nm) caused by the
enhanced permeability and retention effect (EPR) which was discovered by Maeda
[56–58]. The EPR effect is caused by the difference in anatomical architecture, like
blood vessels, between tumor tissues and normal tissues. Tumor blood vessels
secret massive vascular permeability mediators to dilate the blood vessels. The
morphology and functional defectiveness of these blood vessels lead to the
massive leakage of blood components such as macromolecules and nanomicelles
into tumor tissue[59–61]. Moreover, nano-sized micelles can be eliminated more
rapidly from healthy organs than from tumor environment via lymphatic drainage.
Therefore, nanomicelles with typical size range less than 200nm are beneficial to
implement passive targeting.
1.3.2.3 Tumor active targeting strategy of nanomicelles using hyaluronic
acid
Hyaluronic acid (HA) is an endogenous linear anionic polysaccharide which
plays significant roles in biological functions, such as maintaining cell integrity,
extracellular matrix organization, promoting cell motility and angiogenesis [62–64].
It is a natural, biodegradable, non-immunogenic and biocompatible polymer, and
owing to its affinity to specifically recognize overexpressed CD44 receptor. CD44
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is a type 1 transmembrane glycoprotein found on hematopoietic cells, fibroblasts,
and numerous tumor cells. Compared to normal cells, CD44 has higher expression
on the surface of many different types of carcinomas including triple negative
breast cancer [65–68]. Multiple investigators have modified HA with the carrier as
an ideal biomaterial for drug delivery cancer therapy [69–71]. Active targeting drug
carriers can overcome the limitation of the passive targeting approach resulting in
the high accumulation of the drugs in the tumor site and less cytotoxicity to normal
cells. Passive targeting can only work in highly permeable solid tumors [15].
Therefore, the efficacy of chemotherapeutics can be addressed based on
modifying an active targeting ligand, such as monoclonal antibodies [72,73],
peptide ligands[74–76] and small molecules [77,78], which can enhance the
cellular affinity of tumor cells due to highly expressed specific receptors on the
tumor cell surface. Many studies have shown the ability of nanovehicles such as
nanoparticles [79], nanomicelles [34], liposomes [80] and dendrimers [12,18,36] ,
to deliver chemotherapeutic drugs.
1.3.2.4

Styrene-Maleic

Acid

(SMA)

Copolymer

with

D-α-Tocopherol

polyethylene glycol 1000 succinate (Vitamin E TPGS)
Previous studies have shown that SMA micelles exhibited a high drug
loading and encapsulation efficiency, and could solve the poor aqueous solubility
issue of many anticancer compounds. The SMA polymer conjugate with anticancer
compound (SMANCS) has been approved for human clinical use[81,82]. D-αTocopherol polyethylene glycol 1000 succinate (Vitamin E TPGS) is a derivative
of the natural vitamin E ( PEGylated vitamin E), and has been approved by the
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United State Food and Drug Administration (FDA) as well as the European Food
Safety Authority (EFSA) as a safe pharmaceutical adjuvant in drug formulations
[83,84]. TPGS is a P-glycoprotein inhibitor, which can inhibit the function of the
efflux pump to overcome the multidrug resistance (MDR) in cancer cells [85–87].
Meanwhile, TPGS can enhance solubility, absorption, permeation and improve
cellular uptake of the chemotherapeutics agents, making it a promising strategy
for drug delivery system [88–90].
The aim of this study is to build up the hyaluronic acid decorated
nanomicelles to achieve active targeting to CD44 receptor which is overexpressed
on cancer cells (scheme 1.) We have studied the ability to form micelles of SMATPGS copolymer and its ability to target cancer cells by passive targeting and
active targeting using HA as targeting ligand[91,92]. The resulting conjugate (HASMA-TPGS) can self-assemble into nanomicelles and encapsulate the
hydrophobic drug CDF. The physicochemical characterization, in vitro cellular
uptake and cytotoxicity of micelles were evaluated in detail.
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Scheme 1. Schematic illustration of synthesis HA-SMA-TPGS conjugate and selfassembly of SMA-TPGS-CDF and HA-SMA-TPGS-CDF to form nanomicelles in
overexpressed CD44 receptor cancer cells.
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CHAPTER 2. EXPERIMENTAL DESIGN
2.1. Materials
2.1.1 Reagent
CDF was synthesized as described early. Poly-(styrene-co-maleic
anhydride), SMA (M=1.6 kDa), N-(3-(dimethylamino) propyl)-N’-ethylcarbodiimide
hydrochloride (EDC), 3- [4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide
(MTT), 2’,7’ – Dichlorofluorescin diacetate (H2DCFDA), and Sodium bicarbonate
were purchased from Sigma-Aldrich (St. Louis, MO). Hyaluronic acid (MW = 13
kDa) was purchased from Lifecore Biomedical (Chaska, MN). D-α-Tocopherol
polyethylene glycol 1000 succinate (Vitamin E TPGS) was purchased from Antares
health products, INC. All the other reagents used were of analytical grade and used
without any modification.
2.1.2 Cells line
The human lung adenocarcinoma cell line A549 (non-small cell lung cancer)
was used for our study which is based on the earlier reports of its sensitivity to
cerium oxide nanoparticles. The cells lines were maintained in Kaighn’s
Modification of Ham’s F-12 Medium (F-12K Medium, Thermo Fisher Scientific,
USA) supplemented with 10%(v/v) Fatal Bovine Serum (FBS, Thermo Fisher
Scientific, USA), penicillin (100 units/Ml) and streptomycin (100μg/Ml) as standard
culture conditions. The human breast epithelial cell line MCF10A were cultured in
Mammary Epithelial Basal Medium (MEBM™, Lonza Walkersville, Inc)
supplemented with 100 ng/ml cholera toxin (Sigma-Aldrich, USA), BPE 2.0ml, Hegf
0.5ml, Insulin 0.5ml and Hydrocortisone 0.5ml (MEGM SingleQuots, Lonza
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Walkersville, Inc). Human breast cell lines MDA-MB-231 and MDA-MB-468 were
used as the in vitro model due to its overexpression of CD44 receptor (Human
TNBC cell lines MDA-MB-468 and MDA-MB-231 were given by Dr. Arun Rishi from
Karmanos Cancer Institute and John D. Dingell VA Medical Center, Wayne State
University, Detroit, MI, USA.) All cell lines were cultured in DMEM medium with 10
% fetal bovine serum (FBS) and 1 % penicillin-streptomycin. All the cells line flasks
were placed in a 37 °C incubator with 5% CO2 levels (Forma Steri-Cult
HEPAClass100 CO2 incubator, Thermo Scientific).

2.2. Explore the pH-dependent redox activity in Cerium oxide
nanoparticles for selective cancer cell killing
2.2.1 Characterization of cerium oxide nanoparticles
The CNPs, PEG-CNPs, GLY-CNPs, were characterized for size and zeta
potential using a Beckman Coulter Delsa Nano C DLS (Beckman Coulter, Inc.,
Fullerton, CA) Particle analyzer equipped with a 658 nm He−Ne laser. The
morphologies of three different batches of cerium oxide nanoparticles were
assessed using transmission electron microscopy (TEM) (JEM 2010, Tokyo,
Japan) at an accelerating voltage of 200 Kv and 100,000 X magnification.
2.2.2 Cell viability analysis by MTT assay
In vitro cytotoxicity of free cerium oxide nanoparticles and polymer-coated
cerium oxide nanoparticles was determined using a 3-[4,5-dimethylthiazol-2-yl]-2,
5-diphenyltetrazolium bromide (MTT) assay. A549 cells and MCF10A cells were
seeded in 96-well plates (3000 cells each well), respectively and incubated for 24h.
The cells were treated with different concentration from 0.00001mg to 0.1 mg of
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CNPs, PEG-CNPs, GLY-CNPs. After 24h, the cells were incubated with MTT at
37 °C with 5 % CO2 for 3h. Then the medium was discarded and replaced with by
100ml DMSO in each well. The absorbance was read at 590nm using a highdetection multi-plate reader (Synergy 2, BioTek). Percent of cell viability was
calculated as (OD of sample group / OD of the control group) × 100.
2.2.3 Quantification of intracellular levels of reactive oxygen species (ROS)
The reactive oxygen species (ROS: H2O2) were quantified by fluorescence
spectrum using F-2500/F-4500 Fluorescence Spectrophotometer Instruction.
Briefly, A549 cells (2 x 105 cell/ml) were seeded in 6-well plates incubated for 24h.
The cells were treated with 0.02mg/ml of different formulation of CeO2 sample.
After 24h, the cells were washed with PBS and treated with 30Mm H2DCFDA in
cells incubator. After half hour treatment, A549 cells were detached by scraping
and washed again with PBS; then cells were centrifuged to obtain the pellet. The
pellet was lysed using lysis buffer with protease inhibitor cocktail. Bradford assay
was performed to detect the protein concentration. Cell lysate was used to
determine the fluorescence intensity in fluorescence spectrum. The quantification
of intracellular levels of ROS was evaluated as fluorescence intensity of same
concentration of protein.
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2.3. Hyaluronic acid engineered nanomicelles (HA-SMA-TPGS) for the
targeted delivery of CDF to CD44 overexpressing cancer cells
2.3.1 Synthesis and Characterization of SMA-TPGS Conjugates (Nontargeted) and HA-SMA-TPGS Conjugates (Targeted)
For the synthesis of the targeted and non-targeted conjugates, a known
ratio of HA and TPGS was mixed well in deionized water (DI water) at RT, and 1M
NaHCO3 was added to the solution slowly and stirred for several hours. Then the
pH was raised to 8.9 and Poly- (styrene-co-maleic anhydride) (SMA) was added
dropwise to the HA and TPGS solution under magnetic stirring. After that, the
reaction was done until the solution became clear. Only difference in non-targeted
conjugates is, at beginning HA was not added into the solution. SMA-TPGS
conjugates and HA-SMA-TPGS conjugates were purified by dialysis bag (MW 2
kDa) for 24 h and the solution was lyophilized and characterization by proton
nuclear magnetic resonance spectroscopy (1H NMR) and Fourier transform
infrared spectroscopy (FTIR). The critical micelle concentration (CMC) of SMATPGS and HA-SMA-TPGS was determined by a pyrene fluorescence method. In
briefly, 100 µL of pyrene solution (12 µM in methanol) added into amber color
bottle, and the methanol was evaporated under shaking overnight at room
temperature. 2 ml of the sample solution with a series of concentrations was added
into each amber bottle. The fluorescence spectrum was recorded using F-2500/F4500 Fluorescence Spectrophotometer Instruction. The CMC value is determined
by plotting the fluorescence intensity of excitation wavelengths ratio (I335 nm/ I332 nm)
as a function of polymer concentration.
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2.3.2 Preparation and Characterization of CDF – loaded Nanomicelles
SMA-TPGS-CDF and HA-SMA-TPGS-CDF were prepared according to our
previous reported method[34,93]. First, 100 mg of conjugates polymer was
dissolved in 100 ml of DI water under stirring. Then CDF (30 mg) were dissolved
in 1 ml of DMSO and mixed with the polymer solution. After that 40 mg of EDC
was added dropwise into solution and pH was kept at 5.0 to stir for 30 min. Then
raised pH to 11 and kept for other 30 min. At last, pH was adjusted to 7.8 – 8.0
and the free drug CDF were removed by dialysis bag for 4 – 5 hours (MW 2 kDa).
Eventually, the solution was lyophilized to obtain the final nanomicelles. Average
particle size of CDF – loaded nanomicelles were measured using Dynamic Light
Scattering (DLS, Beckman Coulter Delsa Nano CTM). In addition, the size
distribution and morphology was observed by transmission electron microscopy
(TEM, H-7500, and Hitachi Ltd, Tokyo, Japan).
2.3.3 Drug Encapsulation and Loading
The encapsulation efficiency and drug loading content of CDF-loaded
nanomicelles were determined by high-performance liquid chromatography
(HPLC) analysis. The lyophilized nanomicelles were dissolved in deionized water
and subjected to sonication for removal of encapsulated drug. Then the sample
was quantitatively analyzed by HPLC. The mobile phase consisted of 70%
methanol, 29.55% water and 0.45% formic acid (v/v/v) with 1 ml/min flow rate. The
injection volume was 10µL and it was replicated three times. The UV detection
wavelength in HPLC were set at 447 nm. The encapsulation efficiency and durg
loading efficiency were calculated by the following equations:
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𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 % =

𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐶𝐷𝐹 𝑖𝑛 𝑚𝑖𝑐𝑒𝑙𝑙𝑒𝑠
×100
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐶𝐷𝐹 𝑢𝑠𝑒𝑑

𝐷𝑢𝑟𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =

𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐶𝐷𝐹 𝑖𝑛 𝑚𝑖𝑐𝑒𝑙𝑙𝑒𝑠
×100
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑚𝑖𝑐𝑒𝑙𝑙𝑒𝑠

2.3.4 In vitro Release Profile of CDF-Loaded Nanomicelles
The release of CDF from the SMA-TPGS and HA-SMA-TPGS micelles was
determined in phosphate buffer solution (PBS, PH 7.4). Briefly, SMA-TPGS-CDF
and HA-SMA-TPGS-CDF (1 mg of CDF) were placed in 5 ml PBS (pH 5.5 or 7.4)
containing 0.5% (w/w) Tween-80 in a dialysis bag (MWCO = 2K) and incubated in
20ml of PBS corresponding solution with gentle agitation at 37°C in the dark. The
PBS solution outside the dialysis solution was collected at designated time (1 h, 3
h, 6 h, 9 h, 12 h, 24 h, 36 h, 48 h, and 72 h) and an equivalent volume of fresh
PBS was compensated. The collected PBS solution was determined by HPLC
analysis.
2.3.5 Cellular Uptake Study
In-vitro cellular uptake study was done using both CD44 overexpressed
cells line, MDA-MB-231 and MDA-MB-468. First, 2 ´ 105 cells MDA-MB-231 and
MDA-MB-468 cells were seeded in24-well plate. After 24h, the medium was
removed and the cells were treated with Rhodamine B labeled formulations (SMATPGS-Rho and HA-SMA-TPGS-Rho) diluted with serum free DMEM medium for
3 h. Then all of the medium was removed and the cells were washed three times
with PBS containing 0.1% FBS and fixed with 4% formaldehyde at room
temperature for 15 min. After washing another three times, the nuclei were stained

14

with Hoechst 33342 (10 µg/ml) for 15 min. After washing again, the cellular uptake
was studied using two fluorescence channels: blue for the Hoechst 33342 and red
for the Rhodamine B.
2.3.6 In vitro Cytotoxicity Assay
The cytotoxicity of SMA-TPGS conjugates, HA-SMA-TPGS conjugates,
free CDF, targeted and non-targeted CDF micelles was evaluated by MTT assay.
MDA-MBA-231 and MDA-MB-468 cells were seeded 3000 cells each well in 96well plate with 100 µL of full medium DMEM (10% FBS and 1% antibiotics) and
incubated at 37°C in humidified environment of 5% CO2 overnight to allow cell
attachment. After that, the medium was removed, and different concentrations of
conjugates and CDF micelles were diluted with fresh medium and added into the
cells. After 24 h and 48 h, the medium was removed and 100 µL of 1 mg/ml MTT
in PBS was added to each well. The plates were put back to the incubator for other
4 h. Then removed MTT add 100 µl of DMSO was added to the plates. After gentle
shaking, the absorbance was measured at 595 nm by plate reader. The results
were calculated as the mean percentages of the viability of treated cells relative to
untreated cells. The cell viability was evaluated through the equation:
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =

𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
×100
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠

2.3.7 CD44 Receptor Blocking Assay
The CD44 receptor blockade assay based on the principle of occupying the
CD44 receptor using an excess amount of HA (5 mg/ml), After the CD44 receptor
were blocked, and the cells were treated with different concentrations of
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formulations. The cell viability was evaluated by MTT assay again as described
above.
2.3.8 Flow Cytometry Analysis
MDA-MB-231 and MDA-MB-468 cells (2×105 cells/well) were seeded in 6well plate for overnight at the incubator. After that, free SMA-TPGS conjugated,
HA-SMA-TPGS conjugated, free CDF, SMA-TPGS-CDF and HA-SMA-TPGSCDF were added in FBS-containing-DMEM medium to treat the cells. After the
cells had been incubated for 12 hours, cells were trypsinized and analyzed by
apoptosis assay using Guava Nexin Annexin V assay (EMD Millipore, USA) as
described by the manufacturer. Briefly, the cells were collected with the media to
centrifuge. The pellets were dispersed in PBS containing 1% Fetal Bovine Serum.
Then 150µL of cell dispersion was mixed with 50µL of the Guava Nexin Reagent
and kept in the dark for 10 minutes. The sample was studied for early and late
apoptosis by Guava Easycyte flow cytometer.
2.3.9 Western Blot
The cells were collected with PBS and lysed with lysis buffer. Total protein
content was performed using Bradford assay. An equal amount of protein (30 mg)
was separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane.
For detection of specific protein, nitrocellulose membrane was incubated with
PTEN and NF-κb after blocking in 5% nonfat milk solution. (PTEN, NF-κb
antibodies were purchased from Cell Signaling Technology, USA). HRP-linker
rabbit secondary antibodies were used to detect the immunoreactions and the
Blots was exposed by X-ray film.
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CHAPTER 3. RESULTS
3.1. Explore the pH-dependent redox activity in Cerium oxide
nanoparticles for selective cancer cell killing
3.1.1. Characterization of cerium oxide nanoparticles
The cerium oxide nanoparticles were bought from US Research
Nanomaterial, Inc with the size is 10nm. The TEM image shown below indicates
that the size of cerium oxide nanoparticles is approximately 15 nm. (Figure 1.)

Figure 1. Transmission electron microscopy(TEM) image of CNs, PEG-CNs and
GLY-CNs. Scale bar: 100 nm.
3.1.2. Cell viability analysis by MTT assay
The cytotoxicity results in Figure 2 indicated that both CNPs, PEG-CNPs
and GLY-CNPs demonstrated more cytotoxicity towards A549 cancer cells in low
pH (pH 6.5, generally is tumor environment) compared to normal physiological pH
(pH 7.4, generally is normal tissue environment). However, lower concentration
shows a higher cytotoxicity, which is probably because of the solubility issue of
cerium oxide nanoparticles. The higher concentration of cerium oxide
nanoparticles, the less cerium oxide nanoparticles could be dissolved in aqueous
media. Both the CNPs, PEG-CNPs and GLY-CNPs showed less cytotoxicity in
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normal physiological pH (pH 7.4, generally is normal tissue environment). The
main reason for this bifunctional mode of action is because of the ability of pH dependent redox activity in cerium oxide nanoparticles that can be exploited for
selective cancer cell killing.

Figure 2. In vitro cell viability assay showing % live cells at 24h after treating
MCF10A (normal breast cells) and A549 (lung cancer cells) with NPs at pH 6.5
and 7.4 at various concentrations. Data represent mean ± SD, n=5.
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3.1.3. Quantification of intracellular levels of reactive oxygen species (ROS)
The relative fluorescence intensity indicates the intracellular level of ROS.
As shown in figure 3, both treatments of CNPs, PEG-CNPs and GLY-CNPs clearly
present significantly more ROS compared to untreated control cells. It can be
concluded that the production and elevation of ROS is one of the mechanisms of
anti-tumor activity of cerium oxide under low pH conditions.

Figure 3. Quantification of intracellular ROS (H2O2) in A549 cells at pH 6.5 and 7.4.
The results show all the treatments CNs, PEG-CNs and GLY-CNs at pH 6.5
produce more intracellular ROS (H2O2) compare to pH 7.4 and untreated control
experiment. Data represent mean ± SD, n=3.

3.2. Hyaluronic acid engineered nanomicelles (HA-SMA-TPGS) for the
targeted delivery of CDF to CD44 overexpressing cancer cells
3.2.1 Synthesis and Characterization of TPGS-SMA Conjugates (Nontargeted) and HA-TPGS-SMA Conjugates (Targeted)
The chemical structure of TPGS-SMA conjugates and HA-TPGS-SMA
conjugates was confirmed using 1H NMR and FTIR spectroscopy, as shown in
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figure 5. As showed in the spectrum, the characterized peak of HA appeared at
3.2 – 4.1 ppm (glucosidic H), 4.4 – 4.6 ppm (anomeric H) and SMA appeared at
6.5 – 7.5 ppm, 2.5 ppm and TPGS appeared around 2.0 ppm, 4.0 ppm. Retention
of characteristic peaks in TPGS-SMA conjugated and HA-TPGS-SMA confirmed
the conjugates were successfully synthesized. Furthermore, FTIR spectra in figure
4 of the targeted and non-targeted conjugates showed stretching vibration peak of
the ester group (-- C = O --) of conjugates at 1735 cm-1, also indicating the
formation of TPGS-SMA and HA-TPGS-SMA conjugate.

Figure 4. Fourier transform infrared spectroscopy (FTIR) of native HA, SMA
polymer, TPGS and SMA-TPGS conjugates, HA-SMA-TPGS conjugates are
shown.
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Figure 5. Characterization of HA, SMA, TPGS and SMA-TPGS conjugates and
HA-SMA-TPGS conjugates by proton nuclear magnetic resonance spectroscopy
(1H NMR).
The conjugates in an aqueous phase could self-assemble into micelles
owing to the hydrophobic part in SMA and TPGS. In figure 6A the plotting of
fluorescence intensity of excitation wavelengths ratio (I335/ I332) increase from 0.87
to 1.14 with increasing concentration of conjugates. The CMC of both conjugates
is less than 0.001 mg/ml which indicate a strong tendency of conjugates towards
formation of nanomicelles in water at a lower concentration.
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Figure 6. A) Plots of the fluorescence of excitation wavelengths ration of I335 nm/ I332
nm from pyrene vs. the concentrations of SMA-TPGS and HA-SMA-TPGS in
aqueous solution. (B) Hydrodynamic size of SMA-TPGS-CDF nanomicelles and
HA-SMA-TPGS nanomicelles by DLS. (C) The morphology of SMA-TPGS-CDF
nanomicelles and HA-SMA-TPGS nanomicelles characterized by TEM. Scale bar:
500 nm.
3.2.2 Characterization of CDF-loaded nanomicelles
The average particles size of TPGS-SMA-CDF showed a hydrodynamic
size of 167.6 nm (PDI 0.087) and HA-TPGS-SMA-CDF showed a hydrodynamic
size of 129.4 nm (PDI 0.118) (Figure 6B). The morphology of CDF-loaded
nanomicelles was characterized by TEM (Figure 6C). The data revealed that the
size of TPGS-SMA-CDF is around 150 – 180 nm and HA-TPGS-SMA-CDF is
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around 120 – 150 nm. Both micelles were spherical in shape with a smooth
surface. The particles size visualized by TEM were in agreement with the size
acquired by DLS. The drug CDF encapsulation and loading were evaluated by
HPLC method. The TPGS-SMA-CDF loading was14.9 ± 1.4% and encapsulation
efficiency 84.3 ± 2.4%. The HA-TPGS-SMA-CDF loading was 19.6 ± 1.8% and the
encapsulation efficiency 81.8 ± 3.7% (n=3) respectively.
3.2.3 In vitro release profile of CDF-loaded nanomicelles
As illustrated by figure 7, both SMA-TPGS-CDF nanomicelles and HA-SMATPGS-CDF nanomicelles showed practically identical fast release profiles at
various pH conditions. The cumulative release of CDF for SMA-TPGS-CDF and
HA-SMA-TPGS-CDF micelles in 24h, at pH 7.4 was found to be 67.56%±2.87,
78.65%±2.58. At pH 5.5 it was found to be 57.9%±6.95 and 69.53%±4.01. After
72h, the cumulative release of the CDF for SMA-TPGS-CDF and HA-SMA-TPGSCDF micelles at physiological pH was 84.73%±7.4 and 86.97%±5.85. At lysosomal
pH it was 77.98%±6.9 and 84.59%±6.35, respectively.
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Figure 7. In vitro drug release study of SMA-TPGS-CDF nanomicelles and HASMA-TPGS-CDF nanomicelles incubated in PBS at pH 5.5 and 7.4, 37°C,
respectively. Data are presented as mean ± SD, n=3.
3.2.4 Cellular uptake study
The fluorescence microscopic image (figure 8.) shows the different
wavelength of fluorescence intensity in MDA-MB-231 and MDA-MB-468 cells. The
blue-fluorescence indicated the signal of nuclei stained with Hoechst, and the redfluorescent illustrated the signal of Rhodamine B. However, with both images
presented in MDA-MB-231 and MDA-MB-468 cells, the targeted nanomicelles
showed highest red-fluorescence intensity which corroborated with faster cellular
uptake for the HA-targeted micelles than the non-targeted micelles and free
Rhodamine B. Most probably reason for higher uptake of targeted nanomicelles
was attributed to the HA affinity to CD44 receptor-mediated endocytosis on the
surface of cells.
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Figure 8. Fluorescence microscopic images of (A) MDA-MB-231, and (B) MDAMB-468 cells after 3h incubation with Rhodamine B labeled nanomicelles and free
Rhodamine B. Blue and red colors fluorescence light indicate cell nuclei and
Rhodamine B, respectively.
3.2.5 In vitro Cytotoxicity Assay
The cell viability was determined by MTT assay which investigated the
nanomicelle-cytotoxicity in figure 9. We used human triple negative breast cancer
cell line, MDA-MB-231 and MDA-MB-468, to compare the cytotoxicity of free CDF,
SMA-TPGS-CDF micelles and HA-TPGS-SMA-CDF micelles. HA-TPGS-SAMCDF micelles showed a lower IC50 value compared to non-targeted micelles and
free drug as shown in figure 9A. For MDA-MBA-231, in 24h and 48h the IC50 of
free CDF was 280.4 nM and 161.8 nM. The IC50 of non-targeted micelles, SMATPGS-CDF micelles was 196.1 nM and 96.3 nM. The most affected one were the
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targeted micelles, HA-SMA-TPGS-CDF micelles, the IC50 being 88.7 nM and 59.3
nM. A similar situation was observed in MDA-MB-468 cells, in 24h and 48h the
IC50 of free CDF was 468.8 nM and 151.4 nM. The IC50 of non-targeted micelles,
SMA-TPGS-CDF micelles, was 110.9 nM and 65.6 nM, and with the targeted
micelles, HA-SMA-TPGS-CDF micelles, the IC50 was 99.1 nM and 59.9 nM.
These results suggested that the higher cytotoxicity of targeted micelles could be
attributed to the affinity of targeting ligand to CD44 receptor on the surface of cells.
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Figure 9. 24h and 48h viability assay on MDA-MB-231 and MDA-MB-468 treated
with (A) Free CDF, SMA-TPGS-CDF nanomicelles and HA-SMA-TPGS-CDF
nanomicelles at various total drug concentrations. (B) HA, SMA, TPGS, SMATPGS copolymer, SMA-TPGS copolymer at various total drug concentrations.
Data represent mean ± SD, n=6.
3.2.6 CD44 receptor blocking assay
To further verify whether the uptake of the HA targeted CDF loaded micelles
was due to CD44 receptor, the receptor blocking assay was studied (in figure 10.)
by pre-treating the cells with an excess amount of HA (5 mg/ml) before formulation
incubation. In MDA-MB-231 cells, it was observed that before CD44 receptor
blockade, the IC50 value of 24h treatment free CDF, non-targeted micelles and
targeted micelles were 280.4 nM, 196.1 nM, 88.7 nM. But after the receptor
blockade, the IC50 value of free CDF and non-targeted micelles and targeted
micelles were 279.3 nM, 200.2 nM, 194.2 nM. For 48h treatment the IC50 value of
targeted micelles were changed from 59.3 nM to 94.2 nM. We could also observe
the increasing shift in MDA-MB-468. The increasing IC50 value of targeted
formulation indicated that the overexpression of CD44 receptor in cancer surface
might be the primary pathway for targeted micelles to achieve active targeting.
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Figure 10. In vitro cytotoxicity assay observed at 24h and 48h after CD44 receptor
blockade and treating of MDA-MB-231 and MDA-MB-468 with free CDF, SMATPGS-CDF nanomicelles and HA-SMA-TPGS-CDF nanomicelles at various total
drug concentrations. Data represent mean ± SD, n=6.
3.2.7 Fluorescence activated cell sorting (FACS) analysis
Flow cytometry analysis is, as shown in figure 11, comparing free-CDF,
SMA-TPGS conjugates, HA-SMA-TPGS conjugates, SMA-TPGS-CDF micelles,
HA-SMA-TPGS-CDF micelles. As expected, targeted nanomicelles HA-SMATPGS-CDF induced more apoptosis in both MDA-MB-231 and MDA-MB-468 cells
line. The ratio of double (Annexin V-FITC/PI) – positive cells in MDA-MBA-231 and
MDA-MB-468 of each formulation (free-CDF, SMA-TPGS conjugate, HA-SMATPGS conjugate, SMA-TPGS-CDF micelles, HA-SMA-TPGS-CDF micelles) is
shown in figure 11. Briefly, for MDA-MB-231 cells line, the early apoptosis and total
apoptosis of free CDF, SMA-TPGS-CDF micelles, HA-SMA-TPGS-CDF micelles
was 15.1%, 37.2%, 60.4% and 37.8%, 48.3%, 67.8%, respectively. For MDA-MB468 cells line, the ratio was13.8%, 19.8%, 15.7% and 22.6%, 29.9%, 33.3%. These
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results demonstrated that targeted formulation enhanced the CDF delivery and
accumulation, which are mediated by the targeted ligand HA with CD44 receptor.

Figure 11. Free CDF, SMA-TPGS-CDF nanomicelles and HA-SMA-TPGS-CDF
nanomicelles with an increasing apoptosis measured by FACs using staining of
Annexin V-FITC-FITC and PI in (A) MDA-MB-231 and (B) MDA-MB-468. SMATPGS copolymer, SMA-TPGS copolymer set as control.
3.2.8 Western Blot
The previous study had identified that drug CDF can cause inactivation of
carcinomas signaling pathways and down-regulation of NF-κB and up-regulation
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of PTEN expression level. So, western blot was performed to detect the expression
level of PTEN and NF-κB in protein level after treating with the formulation. In figure
12, in both MDA-MB-231 and MDA-MB-468 cells, it showed a significant downregulation of NF- κB and up-regulation of PTEN in the treatment group. In detail,
compared to free CDF, non-targeted micelles, and targeted micelles, PTEN level
showed in MDA-MB-231, 1.94-fold, 2.52-fold and 3.3-fold upregulated compared
to control respectively. Moreover, in MDA-MB-468, PTEN level displayed 1.54fold, 2.47-fold and 2.52-fold upregulation compared to control. To determine NFκB level the results showed in MDA-MB-231, 0.5-fold, 0.32-fold and 0.21-fold
downregulated compared to control respectively. In MDA-MB-468, NF-κB level
displayed 0.63-fold, 0.33-fold and 0.52-fold downregulation compared to control.

Figure 12. Western blot showing the expression downregulation of PTEN level and
upregulation of NF-κB level in protein level after treating with the CDF, SMATPGS-CDF nanomicelles and HA-SMA-TPGS-CDF nanomicelles in (A) MDA-MB231 and (B) MDA-MB-468 cells.
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CHAPTER 4. DISCUSSION
4.1 Explore the pH-dependent redox activity in Cerium oxide
nanoparticles for selective cancer cell killing
Elevated levels of reactive oxygen species can enhance oxidative stress in
many diseases, including diabetes [94], cardiovascular disease[95], neurological
disorders [96] and cancer[97]. ROS can be characterized as a potential carcinogen
when elevated levels are found in intracellular environments leading to oxidative
stress and even causing cells death due to the DNA and protein damage[98–100].
Redox-responsive cerium oxide nanoparticles can play a versatile role in cancer
therapy due to their ability to induce oxidative stress only under tumorigenic low
pH (~6.4 units) conditions while playing a tissue protective role under normal (7.4)
pH conditions. Therefore, we developed polyethylene glycol polymer (PEG) and
glycine (GLY)-coated cerium oxide nanoparticles to enhance their aqueous
solubility. The size of cerium oxide nanoparticles was less than 20 nm. The cellular
cytotoxicity results and quantification of intracellular levels of reactive oxygen
species showed that cerium oxide nanoparticles in tumor cells were mediated by
the pro-oxidant property of cerium oxide nanoparticles under relative low pH
conditions (pH~6.5) of the tumor microenvironment whereas cerium oxide
nanoparticles played a (cytoprotective) anti-oxidant role, scavenging reactive
oxygen species (ROS) and reducing oxidative stress (under normal pH conditions
or pH~7.4). The main reason of this bifunctional mode of action is because of the
ability of pH-dependent redox activity in cerium oxide nanoparticles that can be
exploited for selective cancer cell killing.
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4.2 Hyaluronic acid engineered nanomicelles (HA-SMA-TPGS) for the
targeted delivery of CDF to CD44 overexpressing cancer cells
The major issue of conventional chemotherapy using small molecule drug
is indiscriminate distribution of the drug to tumor tissue leading to inadequate drug
targeting that also causes toxicity to normal tissue. Most conventional anticancer
agents are also highly hydrophobic and water insoluble. Based on our previous
study, amphiphilic SMA was conjugated with targeting ligand to form a stable selfassembling micelles or nanoparticles to encapsulate chemotherapeutic drugs. The
SMA micelles exhibited a high drug loading and encapsulation efficiency improving
the solubility issue of anticancer compound. The results showed that the micelles
could achieve passive targeting based on EPR effect and active targeting based
on the high affinity of HA to CD44 receptor which is overexpressed in many cancer
cells surface[34,93]. The SMA polymer conjugated with anticancer compound
(SMANCS) has been approved for human clinical use[81,82]. However, multidrug
resistant (MDR) in cancer is one of the main challenge for cancer therapy, after
relapse of the disease. MDR is caused by several mechanisms including drugefflux due to upregulation of P-glycoprotein. In this regard, it was found that vitamin
E TPGS could reduce P-glycoprotein thus inhibiting the efflux pump. Moreover,
TPGS is an amphiphilic compound which can enhance solubility, absorption,
permeation and improve cellular uptake of chemotherapy agents[86,89,90,101].
For these advantages, we report herein, hyaluronic acid decorated styrene-maleic
acid (SMA) copolymer with vitamin E TPGS nanomicelles for efficient drug delivery
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to CD44 receptor overexpressing cancer including triple negative breast cancer,
also addressing the poor aqueous solubility issue of anticancer compounds.
In our previous study, HA-SMA was synthesized and characterized to
deliver anticancer compounds for pancreatic cancer[34]. In this study, we
continued using HA and SMA as our carrier and conjugated with TPGS to develop
a new drug delivery system which can improve the solubility of CDF and overcome
multidrug resistant. The synthesis of HA-SMA-TPGS and SMA-TPGS carrier was
confirmed by FTIR spectrum and 1H NMR (Figure 4. and figure 5.). SMA anhydride
ring had an opening reaction to conjugate with the alcohol groups on TPGS and
HA to form the targeting carrier, HA-SMA-TPGS. For non-targeting carrier, no HA
was used in this reaction. Then HA-SMA-TPGS-CDF and SMA-TPGS-CDF were
prepared using our previous method[102,103]. Next, we tried different ratios of
TPGS and HA to select the smallest size of nanomicelles when it is encapsulated
with CDF. Finally, the hydrodynamic size of HA-SMA-TPGS-CDF was 129.4nm
(PDI 0.118) and for the SMA-TPGS-CDF was 167.6nm (PDI 0.087). TEM image
reconfirmed the size range of both targeted and non-targeted nanomicelles which
was in good consistency with the hydrodynamic size. It has been widely reported
that nano-range delivery system with the size less than 200nm was likely to
achieve long blood circulation effect by hiding to reticuloendothelial system (RES)
and increase distribution in tumor tissue through enhanced permeability and
retention effect (EPR)[60,104]. Our results showed that all the targeted and nontargeted nanomicelles were in an ideal size range to achieve passive targeting
EPR effect and avoiding recognition of RES.
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To determine the self-assembled nanomicelles of HA-SMA-TPGS and
SMA-TPGS carrier in aqueous media, critical micelles concentration (CMC) values
were measured using fluorescence spectroscopy with pyrene as the probe. When
the micelles were formed, when the concentration of HA-SMA-TPGS and SMATPGS increased, the fluorescence excitation spectra intensity lead to the peak
absorbance wavelength shift from l=332nm to l=335nm. The CMC value
calculated by plotting the I335nm/I332nm excitation intensity began to increase
markedly versus the logarithm of the concentration of HA-SMA-TPGS and SMATPGS. The lower CMC value meant both HA-SMA-TPGS and SMA-TPGS were
easy to form nanomicelles in lower carrierconcentration. Drug loading studies for
both targeted and non-targeted micelles showed a high CDF loading. The reason
why targeted micelles showed a higher CDF loading was because of the influence
of HA chains on the surface of micelles that established interior hydrophobic
cavities larger than the non-targeted micelles to encapsulate more drugs.
From the in vitro drug release profiles from targeted and non-targeted
nanomicelles in different pH conditions, acid conditions pH 5.5 (endosomes of
cancer cells) and normal conditions pH 7.4 (normal blood environment) were
simulated. The result showed both HA-SMA-TPGS-CDF and SMA-TPGS-CDF
presented a fast release rate at all conditions. Compared with normal pH (pH 7.4)
and acidic pH (pH 5.) the CDF release rate was slower in acidic pH. One
explanation for that could be polymer in protonated state, causing increased
hydrophobicity of the micelles in media which performed a strong interaction with
the hydrophobic drug, thus constraining CDF release[105]. Compared with
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targeted and non-targeted micelles, HA-SMA-TPGS-CDF displayed a faster rate
of drug release. The faster rate of CDF release may be explained by the influence
of HA chains on the surface of micelles that led to steric stabilization endowed.
Having confirmed the ideal physical and chemical properties of HA-SMATPGS-CDF and SMA-TPGS-CDF nanomicelles. Next step, in vitro cellular uptake
of micelles and intracellular distribution behaviors of Rhodamine B was detected
by fluorescent microscopy in MDA-MB-231 and MDA-MB-468 cells. Both cells
lines showed significant higher red fluorescence intensity in Rhodamine B labeled
targeted formulation compared with the non-targeted formulation after 3h of
incubation. The higher red fluorescence intensity indicated higher intracellular
uptake capabilities. That results implied the targeted formulation, HA-SMA-TPGS,
had a higher intracellular uptake than the non-targeted formulation, SMA-TPGS.
The cytotoxicity of CDF, SMA-TPGS-CDF micelles and HA-SMA-TPGSCDF micelles was monitored using in vitro cytotoxicity assay on MDA-MB-231 and
MDA-MB-468 cells. As shown in figure 9A. CDF and targeted, non-targeted
micelles showed high anticancer activity in both cells, and the cytotoxicity of
targeted micelles was significantly higher than the non-targeted micelles and free
CDF. The results not only showed a dose-dependent cytotoxicity of both micelles
formulations but also displayed a time-dependent cytotoxicity of two micellar
formulations. For the MDA-MB-231 cells, the IC50 of targeted micelles was 1.98fold and 3.16-fold smaller compared to non-targeted micelles and free CDF in 24h,
and for 48h targeted micelles was 1.62-fold and 2.73-fold compared to nontargeted micelles and free CDF. For the MDA-MB-468 cells, the IC50 of HA-SMA-

35

TPGS-CDF micelles was lower by 1.2-fold and 4.73-fold compared to SMA-TPGSCDF micelles and free CDF in 24h, and for 48h targeted micelles was 1.1-fold and
2.52-fold compared to non-targeted micelles and free CDF. The significant
enhancement of anticancer activity of targeted micelles could be attributed to the
HA affinity to CD44 receptor which overexpression the surface of cancer cells. The
reason why the cytotoxicity of targeted micelles compared to non-targeted micelles
is not significantly different in MDA-MB-468, most probably reason was the MDAMB-231 CD44 receptor overexpressing type was CD44+/CD24-, but MDA-MB-468
overexpressing type was CD44+/CD24+[106,107]. The different type of CD44
receptor overexpressing type influenced the affinity of HA to CD44 receptor. The
higher cytotoxicity of HA-SMA-TPGS-CDF micelles revealed that the targeted
nanomicelles were more potent for delivery of CDF compared to non-targeted, free
CDF and polymers control which maintained low cytotoxicity to cancer cells.
Further, CD44 receptor blockade study was performed to confirm the higher
cytotoxicity of targeted micelles was mediated by the affinity of HA to the CD44
receptor. In MDA-MB-231 cells, the increasing shift of IC50 value of 24h was from
88.7 nM to 194.2 nM. For 48h treatment the IC50 value of targeted micelles was
changed from 59.3 nM to 94.2 nM. We could also observe the increasing shift in
MDA-MB-468. An increasing IC50 of HA-SMA-TPGS-CDF micelles could be
observed after blockade CD44 receptor. These results showed that the binding
and internalization of targeted micelles to MDA-MB-231 and MDA-MB-468 could
be competitively inhibited by the saturated amount of HA, which demonstrated that
the CD44 receptor mediated the interaction of targeted formulation.
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The apoptosis assay is shown in figure 11. The percentage of early and late
apoptotic cells after treating with targeted micelles in both two cells lines was
significantly increased. In MDA-MB-231, the percentage of early apoptosis, HASMA-TPGS-CDF micelles was 4-fold and 1.62-fold higher compared to free CDF
and SMA-TPGS-CDF micelles. The percentage of total apoptosis, targeted
formulation was 1.79-fold and 1.4-fold higher compared to free CDF and nontargeted micelles. In MDA-MB-468, the percentage of early apoptosis HA-SMATPGS-CDF micelles was 1.13-fold and 0.8-fold higher compared to free CDF and
SMA-TPGS-CDF micelles. The percentage of total apoptosis, targeted formulation
was 1.48-fold and 1.11-fold higher compared to free CDF and non-targeted
micelles. It should be noted that with non-targeted micelles treated on MDA-MB468 cells, the percentage of early apoptosis cells was higher than target micelles.
The probable reason could be the different type of CD44 receptor on the surface
of the cells. However, for the percentage of total injured cells, the highest treatment
was still targeted micelles. The apoptosis results clearly indicated that HA-SMATPGS-CDF micelles (targeted micelles) were more effective inducing apoptosis
compared with SMA-TPGS-CDF (non-targeted) and free drug.
Based on our previous research, CDF can cause inactivation of carcinomas
signaling pathways consistent with miR-21 and down-regulation of controls
transcription of DNA, NF-κB, and up-regulation of MiR-200 and phosphatase and
tensin homolog (PTEN)[30–32]. So, western blot assays were performed on MDAMB-231 and MDA-MB-468 to determine the protein level of NF-κB and PTEN after
treating with free CDF, non-targeted formulation and targeted formulation. For the
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protein level of PTEN, HA-SMA-TPGS-CDF showed a significant upregulated in
both MDA-MB-231 and MDA-MB-468 compared to SMA-TPGS-CDF, free CDF
and control. Moreover, for the protein NF-κB, targeted formulation displayed a
significant downregulation in both two cells lines compared to non-targeted, free
CDF and control. In these study for NF-κB level presented in MDA-MB-468, the
non-targeted formulation exhibited more downregulation compared to the targeted
formulation. The results could be explained again based on the different type of
CD44 receptor on the surface of MDA-MB-468. Thus, the western blot results
implied the targeted formulation could more upregulate PTEN and downregulate
NF-κB, compared to the non-targeted, free drug and control, which could promote
cancer death and tumor suppressor activity.

4.3. Summary and future direction
In this study, we developed polymer-coated cerium oxide nanoparticles to
enhance the solubility using poly ethylene glycol (PEG) and glycine (GLY). Based
on the pH-dependent cytotoxic profiles shown at low pH only towards tumor cells,
cerium oxide nanoparticles and polymer-coated cerium oxide nanoparticles may
provide a novel strategy for improving selective cancer cell killing. Regarding
delivery of anticancer agents to tumor cells we have developed a new HA-SMATPGS conjugate that can form stable micelles with anticancer drugs. The HASMA-TPGS nanomicelles have been shown to be a promising carrier to enhance
the solubility of CDR with stable small nano-size (less than 200 nm), spherical in
shape with a smooth surface morphology. Low CMC value and high drug loading
capacity were obtained using HA-SMA-TPGS micelles indicating its stability for in
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vivo drug delivery. The cellular uptake, cytotoxicity, flow cytometry and western
blot study confirmed that the targeted nanomicelles with a high affinity to CD44
receptor achieved more cytotoxicity to breast cancer cells. These results indicate
that HA-SMA-TPGS conjugate is able to deliver CDF to treat CD44 positive human
breast cancer cells. The CD44 receptor targeting approach can not only be applied
to triple negative breast cancer but also to a number of cancer cells that
overexpressed CD44 receptor including pancreatic and lungs cancers. In
summary, HA-SMA-TPGS-CDF nanomicelles hold promising potential delivery
approach for intracellular delivery of CDF for the treatment of CD44
overexpressing cancer and to overcome multidrug resistance to chemotherapy.
Based on the promising results shown by the redox modulated cerium oxide
nanoparticles and the cancer cells targeting ability of the nanomicelles formulation
HA-SMA-TPGS-CDF, the future direction of this project is to explore the
combination therapy of the two modalities to achieve synergy for more effective
cancer therapy with reduced side effects.
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ABSTRACT
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Redox-responsive cerium oxide nanoparticles (CNPs) can play a versatile
role in cancer therapy due to their ability to induce oxidative stress under proper
pH conditions. Hyaluronic acid micelles with a high affinity to CD44 receptor which
achieved more cytotoxicity towards cancer cells. The polymer-coated CNPs and
HA-SMA-TPGS-CDF nanomicelles were developed for cancer therapy. The
results showed that the toxicity of CNPs in tumor cells was mediated by the prooxidant property of CNPs under relative low pH conditions (pH~6.5) of the tumor
microenvironment whereas CNPs play a (cytoprotective) anti-oxidant role,
scavenging reactive oxygen species and reducing oxidative stress under normal
pH conditions or pH~7.4. HA-SMA-TPGS-CDF nanomicelles held promising
effective and potentially deliver approach to for intracellular delivery of 3,4difluorobenzylidene diferuloylmethane due to higher accumulation and more
cytotoxicity in cancers. Next, we will fabricate a combined nanodelivery structure
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having cerium oxide nanoparticles and HA-SMA-TPGS copolymer for the
treatment of cancers, warranting further investigations.
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